Loading...
Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
This analysis follows our recent study showing that Canadian public reimbursement delays have lengthened from regulatory approval to listing decisions by public drug plans and delayed public access to innovative medicines, mainly due to processes following the Common Drug Review (CDR) and the pan-Ca...
Na minha lista:
| Udgivet i: | Front Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6387957/ https://ncbi.nlm.nih.gov/pubmed/30833899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01578 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|